Related Experiment Videos
Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study
Philip Kam-Tao Li1, Chi Bon Leung, Kai Ming Chow
1Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong. philipli@cuhk.edu.hk
Summary
Valsartan significantly reduced proteinuria and slowed kidney function decline in patients with IgA nephropathy. This angiotensin-receptor blocker (ARB) offers a promising therapeutic option for managing this chronic kidney disease.
Area of Science:
- Nephrology
- Pharmacology
- Internal Medicine
Background:
- Chronic proteinuric nephropathies are often managed with angiotensin-receptor blockers (ARBs).
- Previous research indicated ARB therapy may reduce proteinuria and slow renal decline.
- The efficacy of valsartan in IgA nephropathy specifically required further investigation.
Purpose of the Study:
- To evaluate the effectiveness of valsartan in treating patients with immunoglobulin A (IgA) nephropathy.
- To assess valsartan's impact on proteinuria and the rate of renal function decline.
Main Methods:
- A double-blind, randomized, placebo-controlled, multicenter study involving 109 patients with IgA nephropathy.
- Patients received either valsartan (80-160 mg/d) or a placebo for 104 weeks.
- Primary endpoint was doubling of serum creatinine or dialysis; secondary outcomes included proteinuria and GFR changes.
Main Results:
- Valsartan treatment led to a significant 33.0% decrease in proteinuria compared to placebo.
- The mean rate of glomerular filtration rate (GFR) decline was significantly slower in the valsartan group.
- While not statistically significant, only 1 patient in the valsartan group reached the primary endpoint versus 4 in the placebo group.
Conclusions:
- Valsartan effectively reduces proteinuria and slows renal deterioration in IgA nephropathy patients.
- The benefits are observed even after adjusting for confounding factors like blood pressure.
- Further studies are needed to confirm the long-term benefits of valsartan in IgA nephropathy.